Anthony J. Yosick

Anthony J. Yosick

Auto-generated profile, based on publicly available information

Anthony J. Yosick

Department of Biomedical Engineering, University of Rochester

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Bioactive Materials
Verified
Journal Article
Open access
MYMing Yan
Ming Yan
BXBaixue Xiao
Baixue Xiao
AYAnthony Yosick
Anthony Yosick
BLBei Liu
Bei Liu
HAHani A. Awad
Hani A. Awad
Regenerating critical-sized long bone defects poses substantial challenges due to limitations of autografts and processed allografts. Biomaterial scaffolds offer versatile alternatives, yet their effectiveness is often constrained by their limited innate osteoinductivity. While growth factors and cells can enhance osteoinduction, the inclusion of biologics in biomaterial scaffolds creates regulatory challenges for clinical translation. To address this, here we describe three-dimensional (3D) printed polycaprolactone (PCL) scaffolds for temporally controlled delivery of osteoimmunomodulatory amorphous calcium phosphate-chitosan nanoparticles (ACPC-NP). In vitro, the ACPC-NP exhibit concentration dependent effects on osteoblasts, monocytes, and osteoclasts. At increasing concentrations up to 500 μg/ml, these nanoparticles stimulate osteogenesis, modulate M2/M1 macrophage polarization, and inhibit osteoclast maturation and activity. Leveraging these concentration-dependent effects in vivo through temporally controlled release of ACPC-NP from 3D-printed PCL scaffolds, we observe the complete regeneration and the restoration of biomechanical strength of critically sized radial defects in rats. Such healing is absent in defects implanted with bare PCL scaffolds or those loaded with calcium-phosphate microparticles. The tunable osteoimmunomodulation by the NP underscores the translational potential of this technology to yield structurally sound and functionally robust bone regeneration outcomes.

1 April 2026 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
DGDylan N Greif
Dylan N Greif
PCPatrick Castle
Patrick Castle
ARAndrew Rodenhouse
Andrew Rodenhouse
NANatnael Ayalew
Natnael Ayalew
AYAnthony J. Yosick
Anthony J. Yosick
IVIlya Voloshin
Ilya Voloshin

17 January 2026 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
AYAnthony J. Yosick
Anthony J. Yosick
ARAndrew Rodenhouse
Andrew Rodenhouse
KJKyle Jerreld
Kyle Jerreld
SLSashank Lekkala
Sashank Lekkala
CMChristine Massie
Christine Massie
CKConstantinos Ketonis
Constantinos Ketonis

14 September 2026 in JBMR Plus
Verified
Journal Article
Open access
AYAnthony J Yosick
Anthony J Yosick
STSophia L Turbide
Sophia L Turbide
ABAndrew J Berger
Andrew J Berger
HAHani A. Awad
Hani A. Awad
Osteoporosis (OP) is a progressive skeletal disorder characterized by reduced BMD and increased risk of fragility fractures. Clinical assessment relies primarily on DXA and the fracture risk assessment tool (FRAX), but limited access and low screening rates motivate investigation of complementary approaches. This human cadaveric study evaluated cortical indices of the second metacarpal, radius, and femur in relation to DXA-based OP status and biomechanically derived fracture susceptibility at the wrist and hip. Cortical measurements were obtained from 39 donor-matched forearms and femurs categorized as normal (n = 8), osteopenic (n = 11), and osteoporotic (n = 20) based on femoral neck (FN) DXA T-score. Simulated fall testing of the distal radius and proximal femur was performed to determine work to fracture, which was used to derive low and high biomechanical fracture susceptibility classifications. Among the cortical indices, metacarpal cortical index (MCI) demonstrated the strongest associations with DXA T-scores and biomechanical outcomes. MCI distinguished normal from osteoporotic classification at the FN (area under the curve [AUC] = 0.938) and 1/3 radius (AUC = 0.986). For biomechanically derived fracture susceptibility, FN T-score demonstrated strong discrimination at both the femur (AUC = 0.917) and wrist (AUC = 0.851), while MCI yielded AUCs of 0.847 and 0.855, respectively. FRAX hip fracture probability yielded AUCs of 0.911 at the femur and 0.830 at the wrist. These findings demonstrate associations between MCI, DXA-based OP status, and biomechanical fracture susceptibility in this cadaveric cohort. MCI may therefore warrant further investigation as a complementary screening approach, particularly where access to DXA is limited. Validation in larger clinical cohorts with prospective fracture outcomes is needed to determine its clinical utility.